AI Talks: Transforming the diagnosis of genetic disorders

In the context of the interactive activities organised by SKEL | The AI Lab, a talk took place from the company gMendel® with invited speaker Dr Christos Kyriakidis, Co-founder & CEO.

The talk titled Transforming the diagnosis of genetic disorders was held online on 29 September 2021, while a Q&A session followed the presentation.

Watch the session here:

Short bio: After completing a Ph.D. in Biochemistry (Crystallography), an M.Sc. in Physics and an MBA (Master of Business Administration), C. Kyriakidis has pursued a career in commercial functions in pharma and MedTech companies. His general management and business development skills were developed while running a $130 million international business and as a founder of a biosciences start-up company (sold in 2014). His marketing and project management skills were developed in an FMCG environment (L’Oréal), from where he moved to pharmaceutical/medical devices industry (Novo Nordisk, ALK, GN), including subsidiary (Brazil), regional (Asia, Eastern Europe, Latin America, Middle East & Africa) and global headquarter positions (Denmark). As a scientist, who moved to commercial operations, he takes every opportunity to search for and apply new methods, technologies, and approaches in the organizations where he works. Mr Kyriakidis has been a people leader for 20 years, developing multicultural diverse teams to reach their best potential through high engagement and has lived in 9 countries and done business in 60+ countries on all continents.

gMendel® is a Danish start-up aiming to transform the diagnosis of genetic disorders for better disease management. Despite continuous advances in genetic testing technology, accurate diagnosis and treatment remain a great challenge for patients, doctors, and healthcare systems. The current clinical protocol does not always provide an accurate diagnosis or a diagnosis at all, due to prohibitive costs of advanced technologies and scarce expert knowledge. The gMendel® approach is from diagnosis to treatment. Their transformative approach bridges the gap between new generation genomic tools and their clinical implementation, providing a shorter path to accurate diagnosis and potential treatment. This means reduced time and costs for patients and healthcare providers.

More News


SUSTAIN launches its Open Calls for SMEs
AI Ecosystem Forum 2023 – AI-on-Demand platform & (E)DIHs
ahedd coordinates Smart Attica EDIH
ahedd at the 3rd DIH² Convention
ahedd at the “Boosting Widening Digital Innovation Hubs – BOWI” event
ahedd’s initiative “1000 Pioneers for AI in Greece” at the UNESCO’s IRCAI Top 100 AI projects
Smart Attica EDIH at the “Innovation in Northern Greece and the bodies that support it 4.0” conference
“AI powering your SME – Tools, Strategies & Opportunities” webinar co-organised by ahedd DIH
ahedd DIH is an “X2.0 Driving Deep Tech Growth” Impact Builder
ahedd at the 1st Demo Common Days